Patents by Inventor Mathieu CASTELA

Mathieu CASTELA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12624341
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
    Type: Grant
    Filed: January 27, 2025
    Date of Patent: May 12, 2026
    Assignee: SCARCELL Therapeutics
    Inventors: Antoine Lafont, Mathieu Castela
  • Publication number: 20250263656
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.
    Type: Application
    Filed: April 17, 2025
    Publication date: August 21, 2025
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA
  • Publication number: 20250243457
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from canine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of canine cell therapies are provided.
    Type: Application
    Filed: April 17, 2025
    Publication date: July 31, 2025
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA
  • Patent number: 12351823
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: July 8, 2025
    Assignee: Scarcell Technologies
    Inventors: Antoine Lafont, Mathieu Castela
  • Publication number: 20250207093
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
    Type: Application
    Filed: January 27, 2025
    Publication date: June 26, 2025
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA
  • Patent number: 12297454
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from canine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of canine cell therapies are provided.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: May 13, 2025
    Assignee: Scarcell Technologies
    Inventors: Antoine Lafont, Mathieu Castela
  • Patent number: 12258579
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: March 25, 2025
    Assignee: Scarcell Technologies
    Inventors: Antoine Lafont, Mathieu Castela
  • Publication number: 20240307454
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.
    Type: Application
    Filed: April 17, 2023
    Publication date: September 19, 2024
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA
  • Publication number: 20240309323
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
    Type: Application
    Filed: April 17, 2023
    Publication date: September 19, 2024
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA
  • Publication number: 20240307456
    Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from canine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of canine cell therapies are provided.
    Type: Application
    Filed: April 17, 2023
    Publication date: September 19, 2024
    Applicant: SCARCELL Therapeutics
    Inventors: Antoine LAFONT, Mathieu CASTELA